Compare Amphastar Pharmaceuticals Inc (AMPH) vs Funko Inc (FNKO) Price & Performance

AMPH trades at $18.72, down 1.58% with bearish technical signals despite oversold RSI readings. The company reported mixed Q1 2026 results with EPS of $0.42 missing estimates of $0.70, continuing a trend of recent earnings disappointments. Valuation metrics appear reasonable with P/E of 11.29 and P/B of 1.07, while profitability remains solid with 47.34% gross margins. Recent news includes a Zacks Strong Sell rating and ongoing securities law investigation.

The stock faces near-term headwinds from earnings misses and negative analyst sentiment, though current valuations provide some downside protection. Upside potential exists if the company can execute its strategic pivot to proprietary drugs and biosimilars while managing BAQSIMI discount pressures. Key risks include ongoing legal scrutiny and competitive pressures in the generic drug market.

FNKO trades at $5.58, up 3.91% with a neutral technical signal despite bullish moving averages. The company shows mixed fundamentals with revenue declining to $908M in 2025 and a net loss of $67M, though recent quarters beat EPS estimates. Analyst consensus is divided with 42.9% buy ratings, while positive news includes new product launches and Q1 2026 revenue growth to $200.9M. Cash flow improved to a net positive $7.5M in 2025 from negative trends in prior years.

Outlook remains cautious due to persistent losses and high debt, but recent execution improvements and product innovation offer potential upside. Key risks include margin pressure and competitive threats in the collectibles market. Investors should weigh the bullish analyst sentiment against fundamental challenges before considering a position.